유방암 진단 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 유형별, 제품별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Breast Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Product, By Application, By End-use, By Region, and By Competition, 2020-2030F
상품코드:1881453
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 유방암 진단 시장은 2024년에 629억 8,000만 달러로 평가되었으며, 2030년까지 CAGR 11.21%로 성장하여 1,191억 4,000만 달러에 달할 것으로 예측됩니다.
세계 유방암 진단 시장은 유방암의 발견, 특성화, 경과 관찰을 목적으로 설계된 다양한 전문 검사, 영상 진단법, 생검법 등을 포괄하고 있습니다. 시장 성장의 주요 요인으로는 전 세계 유방암 발병률 증가, 공중보건 인식 제고 활동 강화, 정부 주도의 조기 발견 및 검진 프로그램 추진 등을 꼽을 수 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
629억 8,000만 달러
시장 규모 : 2030년
1,191억 4,000만 달러
CAGR : 2025-2030년
11.21%
가장 빠르게 성장하는 부문
소모품
최대 시장
북미
주요 시장 촉진요인
전 세계 유방암 발생률의 증가는 유방암 진단 시장의 기본적인 촉진요인으로 작용하고 있습니다. 신규 환자 수가 증가함에 따라 조기 발견을 촉진하고 환자의 치료 결과를 개선하기 위해 전 세계적으로 스크리닝 및 진단 능력의 확대가 요구되고 있습니다.
주요 시장 과제
고도의 진단 기술에 따른 막대한 비용은 세계 유방암 진단 시장의 성장을 저해하는 중요한 도전 요인입니다. 이러한 높은 비용은 특히 의료 예산이 부족한 개발도상국에서 중요한 검진 및 진단 절차에 대한 접근성을 제한하고 있습니다.
주요 시장 동향
조기 발견과 경과 관찰을 위한 액체 생검의 확대 적용은 유방암 진단의 중요한 전환점입니다. 혈액 샘플에서 순환 종양 DNA와 세포를 분석하는 이 비침습적 기술은 기존 조직 생검에 비해 부담이 적은 대안을 제공하여 조기 발견과 지속적인 질병 모니터링을 가능하게 합니다.
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 유방암 진단 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
종류별(영상 진단, 생검, 유전체 검사, 혈액 검사, 기타)
제품별(플랫폼 기반 제품, 기기 기반 제품)
용도별(스크리닝, 진단·예측, 예후, 조사, 기타)
최종사용자별(병원·진료소, 진단 센터·의료 검사기관, 기타)
지역별
기업별(2024)
시장 맵
제6장 북미의 유방암 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 유방암 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 유방암 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 유방암 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 유방암 진단 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병
제품 출시
최근 동향
제13장 세계의 유방암 진단 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 경쟁 구도
Baxter Pharmaceuticals India Private Limited.
Bristol-Myers Squibb India Private Limited.
Cipla Ltd.
Roche Products(India) Private Limited.
Glenmark Pharmaceuticals Ltd.
Lupin Ltd
Abbott India Laboratories Limited
BIO-RAD LABORATORIES(INDIA) PRIVATE LIMITED.
Siemens Healthcare Private Limited.
Thermo Fisher Scientific India Private Limited.
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
KSM
영문 목차
영문목차
The Global Breast Cancer Diagnostics Market, valued at USD 62.98 Billion in 2024, is projected to experience a CAGR of 11.21% to reach USD 119.14 Billion by 2030. The Global Breast Cancer Diagnostics Market encompasses an array of specialized tests, imaging modalities, and biopsy procedures engineered to detect, characterize, and monitor breast cancer. Market growth is primarily driven by the escalating global incidence of breast cancer, augmented public health awareness campaigns, and governmental initiatives promoting early detection and screening programs.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 62.98 Billion
Market Size 2030
USD 119.14 Billion
CAGR 2025-2030
11.21%
Fastest Growing Segment
Consumables
Largest Market
North America
Key Market Drivers
The increasing global incidence of breast cancer serves as a fundamental driver for the breast cancer diagnostics market. A rising number of new cases necessitates expanded screening and diagnostic capabilities worldwide to facilitate early detection and improve patient outcomes. This persistent disease burden creates consistent demand for diverse diagnostic solutions, from initial screening to definitive diagnosis and staging. For example, according to the American Cancer Society's Breast Cancer Facts & Figures 2024, an estimated 310,720 new cases of invasive breast cancer were expected to be diagnosed in the United States in 2024, underpinning the critical need for effective diagnostic tools. This widespread health challenge reinforces the market's expansion, with breast cancer being the most common cancer in women in 157 countries out of 185 in 2022, as reported by the World Health Organization in February 2024.
Key Market Challenges
The substantial cost associated with advanced diagnostic technologies represents a significant challenging factor impeding the growth of the Global Breast Cancer Diagnostics Market. These high expenses restrict accessibility to crucial screening and diagnostic procedures, particularly within developing economies where healthcare budgets are often constrained. This financial barrier limits the widespread adoption of comprehensive diagnostic screening protocols across various regions.
Key Market Trends
The growing adoption of liquid biopsy for early detection and monitoring represents a pivotal shift in breast cancer diagnostics. This non-invasive technique, which analyzes circulating tumor DNA or cells from a blood sample, offers a less burdensome alternative to traditional tissue biopsies, facilitating earlier detection and ongoing disease surveillance. Its utility is becoming increasingly recognized as research progresses, with clinical applications expanding beyond advanced disease. According to the American Society of Clinical Oncology, in January 2024, five liquid biopsy companion diagnostic assays were approved by the U. S. Food and Drug Administration for their clinical application in the diagnosis of cancer.
Key Market Players
Baxter Pharmaceuticals India Private Limited.
Bristol-Myers Squibb India Private Limited.
Cipla Ltd.
Roche Products (India) Private Limited.
Glenmark Pharmaceuticals Ltd.
Lupin Ltd
Abbott India Laboratories Limited
BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
Siemens Healthcare Private Limited.
Thermo Fisher Scientific India Private Limited.
Report Scope:
In this report, the Global Breast Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Breast Cancer Diagnostics Market, By Type:
Imaging
Biopsy
Genomic Tests
Blood Tests
Others
Breast Cancer Diagnostics Market, By Product:
Platform-based Products
Instrument-based Products
Breast Cancer Diagnostics Market, By Application:
Screening
Diagnostic and Predictive
Prognostic
Research
Others
Breast Cancer Diagnostics Market, By End-use:
Hospitals & Clinics
Diagnostic Centers and Medical Laboratories
Others
Breast Cancer Diagnostics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Breast Cancer Diagnostics Market.
Available Customizations:
Global Breast Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Breast Cancer Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Others)
5.2.2. By Product (Platform-based Products, Instrument-based Products)
5.2.3. By Application (Screening, Diagnostic and Predictive, Prognostic, Research, Others)
5.2.4. By End-use (Hospitals & Clinics, Diagnostic Centers and Medical Laboratories, Others)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Breast Cancer Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Product
6.2.3. By Application
6.2.4. By End-use
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Breast Cancer Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Product
6.3.1.2.3. By Application
6.3.1.2.4. By End-use
6.3.2. Canada Breast Cancer Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Product
6.3.2.2.3. By Application
6.3.2.2.4. By End-use
6.3.3. Mexico Breast Cancer Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Product
6.3.3.2.3. By Application
6.3.3.2.4. By End-use
7. Europe Breast Cancer Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Product
7.2.3. By Application
7.2.4. By End-use
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Breast Cancer Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Product
7.3.1.2.3. By Application
7.3.1.2.4. By End-use
7.3.2. France Breast Cancer Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Product
7.3.2.2.3. By Application
7.3.2.2.4. By End-use
7.3.3. United Kingdom Breast Cancer Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Product
7.3.3.2.3. By Application
7.3.3.2.4. By End-use
7.3.4. Italy Breast Cancer Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Product
7.3.4.2.3. By Application
7.3.4.2.4. By End-use
7.3.5. Spain Breast Cancer Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Product
7.3.5.2.3. By Application
7.3.5.2.4. By End-use
8. Asia Pacific Breast Cancer Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Product
8.2.3. By Application
8.2.4. By End-use
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Breast Cancer Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Product
8.3.1.2.3. By Application
8.3.1.2.4. By End-use
8.3.2. India Breast Cancer Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Product
8.3.2.2.3. By Application
8.3.2.2.4. By End-use
8.3.3. Japan Breast Cancer Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Product
8.3.3.2.3. By Application
8.3.3.2.4. By End-use
8.3.4. South Korea Breast Cancer Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Product
8.3.4.2.3. By Application
8.3.4.2.4. By End-use
8.3.5. Australia Breast Cancer Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Product
8.3.5.2.3. By Application
8.3.5.2.4. By End-use
9. Middle East & Africa Breast Cancer Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Product
9.2.3. By Application
9.2.4. By End-use
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Breast Cancer Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Product
9.3.1.2.3. By Application
9.3.1.2.4. By End-use
9.3.2. UAE Breast Cancer Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Product
9.3.2.2.3. By Application
9.3.2.2.4. By End-use
9.3.3. South Africa Breast Cancer Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Product
9.3.3.2.3. By Application
9.3.3.2.4. By End-use
10. South America Breast Cancer Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Product
10.2.3. By Application
10.2.4. By End-use
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Breast Cancer Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Product
10.3.1.2.3. By Application
10.3.1.2.4. By End-use
10.3.2. Colombia Breast Cancer Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Product
10.3.2.2.3. By Application
10.3.2.2.4. By End-use
10.3.3. Argentina Breast Cancer Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Product
10.3.3.2.3. By Application
10.3.3.2.4. By End-use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Breast Cancer Diagnostics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Baxter Pharmaceuticals India Private Limited.
